Physician profile

Ramya Mallareddy

Internal Medicine · Sacramento, CA

NPI 1952609430

$232.41

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$16.49

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $51.22 2019-2020
Ucb, INC. $32.17 2019
Philips North America LLC $31.07 2019
Janssen Pharmaceuticals, INC $29.99 2019
Pfizer INC. $21.42 2019
Otsuka America Pharmaceutical, INC. $18.76 2019
Merck Sharp & Dohme LLC $17.03 2019
Kyowa Kirin, INC. $16.49 2023 Crysvita
Abbvie INC. $14.26 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Ramya Mallareddy

$232.41

in general payments reported 2019-2025

Years
2019-2023
Top company
Astrazeneca Pharmaceuticals LP

https://glasscript.com/doctor/224379/ramya-mallareddy

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.